Stocks
Novartis AGNVS
NYSEHealthcarePharmaceuticals$153.44-0.53%
A Switzerland-based pharmaceutical manufacturer focused on innovative prescription medicines across oncology, immunology, neuroscience, and cardiovascular diseases. The company generates revenue from a portfolio of patented drugs and late-stage pipeline assets, following the 2023 spin-off of its generics business, Sandoz. Investors closely monitor its clinical trial results, regulatory approvals, and patent expirations, which drive long-term revenue growth and margin stability.
Market Cap: $296.6B52W Range: $97.72 – $170.46
Congressional Interest in Novartis AG (NVS)
14 members of Congress have disclosed 50 trades in Novartis AG (NVS), a Healthcare company. The buy/sell breakdown shows 23 purchases versus 27 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
50
Unique Politicians
14
Buys
23
Sells
27
Who in Congress Is Trading NVS?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-31 | Alan Armstrong | buy | $1K – $15K |
| 2026-03-30 | Alan Armstrong | buy | $15K – $50K |